Rigel Pharmaceuticals Inc (RIGL)

[Citrati]

Rigel currently has five product candidates in development: fostamatinib, an oral SYK inhibitor expected to enter Phase 3 clinical trials for ITP and a Phase 2 clinical trial for IgA Nephropathy in 2014; R348, a topical JAK/SYK inhibitor for chronic dry eye currently in Phase 2 clinical trials; R118, an AMPK activator in Phase 1; and two oncology product candidates in Phase 1 development with partners BerGenBio and Daiichi Sankyo.

Rigel has signed partnerships with numerous leading pharmaceutical companies including, AstraZeneca, Daiichi Sankyo, Pfizer, Merck, Johnson & Johnson, and Novartis. During our collaborations with many of these organizations, they added new programs or extended their relationship with Rigel beyond the scope of the initial agreements. These partnership programs are in addition to Rigel's own proprietary research and product development programs.

Current partnership summary:

DEVELOPMENT
PARTNER MECHANISM INDICATION YEAR

AstraZenenca IL13/IL4 inhibition Chronic Asthma 2012


BerGenBio Axl kinase inhibition Oncology 2011


Daiichi Sankyo Ubiquitin ligase target Oncology 2002


All information from company website.